Abbott's Strength Comes On Two Major Products
Abbott Laboratories (ABT) is in a great spot, according to Sanford C. Bernstein analyst Derrick Sung. "They're one of my top picks," he said. The drugmaker makes a number of notable names, but two to watch are Humira and Xience. Humira is expanding in a number of areas, such as Crohn's disease and psoriasis. Much of Abbott's success is tied to this one drug, Sung says. It's nearly 20% of top-line profit. Sung estimates its 2009 sales at $5.5
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here